Smith & Nephew plc (SNNUF) Fair Value & Analysis
Healthcare · US · Market cap $12.3B
Smith & Nephew plc
SNNUF · US
Fair value as of: Jul 19, 2026
From 25 valuation models · updated 2 days ago
Share price +10.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $11.18 – $18.40 · fair‑value band $8.62 – $20.77 · the $15.00 price screens above the $14.79 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Smith & Nephew plc (SNNUF) currently trades at $15.00, while our model-based Fair Value estimate is $14.79, implying the stock looks roughly 1.4% fairly valued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Smith & Nephew plc generated revenue of $6.2B at a net margin of 10.1%. Revenue grew 7.4% year over year. It earns a return on equity of 11.8%. Net debt stands at $2.8B. Fundamentals as of Jul 19, 2026
Our scenario range runs from $8.62 (bear case) to $20.77 (bull case); at $15.00, the current price sits within that range. The share trades about 19% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -21% fair-value upside, at -1%, SNNUF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Smith & Nephew plc reported revenue of $6.3B in FY2025 versus $5.2B in FY2021, a compound +4.9%/yr. Reported net income was $639M in FY2025, compounding +5.1%/yr from FY2021.
Is SNNUF fairly valued? → Check now
Recent news
- New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
- New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
- Alkami Technology, Diebold Nixdorf, and 3 More Stocks See Action From Activist Investors.
- Is Smith & Nephew plc (SNN) A Good Stock To Buy Now?
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $89.17 | $70.59 | -21% |
| Stryker Corporation SYK | $308.84 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$211.05 | R$29.52 | -86% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $69.07 | $65.56 | -5% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| Koninklijke Philips N.V PHG | $26.61 | $12.54 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Smith & Nephew plc (SNNUF) undervalued?
What is the fair value of SNNUF?
What is the quality score of SNNUF?
What is the revenue of Smith & Nephew plc (SNNUF)?
What is the net profit margin of SNNUF?
Does Smith & Nephew plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Smith & Nephew plc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.